#mbs303
mbs303915cdembs303cd20cd3b mbs303tMBS303 is a CD20×CD3 T-cell-engaging bispecific antibody that has a novel 2:1 (CD20:CD3) confuration to kill malnant B cells. This dose-escalation phase Ⅰ trial evaluated the safety
IDR 10.000
IDR 100.000
Disc -90%